Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

2010198 citationsJournal Articlebronze Open Access

Authors

C. Lance Cowey

Chirag Amin

Abstract

The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 9, pp. 1502-1507

DOI: 10.1200/jco.2009.24.7759

Field-Weighted Citation Impact: 22.85